Proceedings of the 26th European Paediatric Rheumatology Congress: part 1

Abstract

The proceedings contain 495 papers. The topics discussed include: validation of the recently developed evidence-based eurofever classification criteria for hereditary recurrent fevers (HRF) and PFAPA; performance of the autoinflammatory disease activity index (AIDAI) in patients with colchicine-resistant FMF, HIDS/MKD and traps: results from a pivotal, phase 3 trial of canakinumab; interrator reliability of a standardized scoring tool to report MRI findings in chronic nonbacterial osteomyelitis; impact of pediatric rheumatic diseases on caregivers multiassessment questionnaire: caregivers questionnaire; treat-to-target using first-line treatment with recombinant IL-1 receptor antagonist is highly effective for systemic JIA: a 5 year follow-up study; clinical outcomes following mycophenolate mofetil vs. cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis; worldwide coherence of association of Kawasaki disease to massive agricultural cropland byproducts; correlations of type I interferon score and interferon induced chemokines (CXCL10 and CXCL9) with cutaneous and muscular disease activity in juvenile dermatomyositis; the interaction between genetic risk factors and age of disease onset in juvenile dermatomyositis; and early aggressive treatment decreases pain in patients with juvenile idiopathic arthritis.